Novartis Institutes for BioMedical Research, Translational Medicine, Basel, Switzerland.
Novartis Institutes for BioMedical Research, Translational Medicine, Cambridge, Massachusetts, USA.
Clin Pharmacol Ther. 2018 May;103(5):802-814. doi: 10.1002/cpt.1010. Epub 2018 Feb 1.
There remains a large unmet need for new therapies in the treatment of heart failure with reduced ejection fraction (HFrEF). In the early drug development phase, the therapeutic potential of a drug is not yet fully understood and trial endpoints other than mortality are needed to guide drug development decisions. While a true surrogate marker for mortality in heart failure (HF) remains elusive, the successes and failures of previous trials can reveal markers that support clinical Go/NoGo decisions.
在治疗射血分数降低的心力衰竭（HFrEF）方面，仍然存在大量未满足的新疗法需求。在药物早期开发阶段，药物的治疗潜力尚未完全了解，除了死亡率以外，还需要其他试验终点来指导药物开发决策。虽然心力衰竭（HF）的真正死亡率替代标志物仍然难以捉摸，但以前试验的成败可以揭示支持临床决策的标志物。
